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Background: Gas6 protein is involved in pulmonary embolism (PE) and acute inflammation in
animal models.
Methods: We enrolled 82 consecutive patients with acute dyspnea and suspected PE (Geneva
score with high (HCP) or low/intermediate clinical probability (LICP) þ D-dimer 0.5 mg/mL)
and 29 age-matched healthy volunteers. According to clinical and instrumental evaluations
the following diagnoses were obtained: heart failure (HF), pulmonary or systemic infection
(I), PE, or no illness (N). Twenty-two patients were excluded due to oral anticoagulation (9),
lack of CT angiography or pulmonary scintigraphy (6), plasma creatinine 3 mg/dL (3), and
pulmonary cancer (4). Plasma Gas6 was measured with a validated enzyme-linked immuno-
assay. Non-parametric tests and accuracy measures were calculated.
Results: Out of 60 patients included, 8 were N, 12 HF, 11 I and 29 PE. Gas6 median value in the
N group (20.4 ng/mL, interquartile range 17.6e21.6) matched that of healthy volunteers, 19.1
(17.2e21.4). Median Gas6 values in HF, 26.4 (21.6e33.3) and I groups, 34.1 (30.0e38.7), were
significantly higher than those in PE 18.2 (16.3e23.3) or N (KruskaleWallis test p  0.05)
groups. Gas6 test improved PE diagnosis with an area under the curve of 0.80 and 0.91 (in
all and LICP patients). A 24 ng/mL threshold excluded PE in 33% of LICP patients without
loosing any diagnosis.21 373 3848; fax: þ39 0321 373 3841.
nipmn.it, avanzi@med.unipmn.it (G.C. Avanzi).
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590 P.P. Sainaghi et al.Table 1 Criteria for the dyspne
Diagnosis Definition
N Absence on acute
cardiac or pulmonary
disease
HF Worsening chronic
or de novo heart failu
or pulmonary edema
with elevated, normal
or reduced systolic
blood pressure28
I Pulmonary infection,
systemic infection,
sepsis
PE Pulmonary embolismConclusions: The data link Gas6 protein to infection/inflammation, but not to PE, in humans.
Gas6 assay was useful in PE diagnosis, improving D-dimer accuracy particularly in LICP
patients, and limiting false positives.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
The differential diagnosis of acute dyspnea is often chal-
lenging because it is difficult to identify the underlying
disease rapidly. Only a few biomarkers are reliable;1 even
more so in relation to pulmonary embolism (PE), in which
the only reliable plasma marker is D-dimer.2 Gas6 (growth-
arrest-specific protein 6) is a 75-kDa protein with 44%
homology to coagulation protein S.3,4 Both proteins bind to
tyrosine kinase Tyro3 family receptors (Axl, Tyro-3, Mer)
but Gas6 has greater affinity for Axl.5e8 These receptors
have been found to be coexpressed with Gas6 protein in
CNS, endothelium, platelets and monocytes.9e12
There is evidence to support Gas6 protein involvement in
the pathogenesis of PE: gas6 / mice are protected from
induced venous thromboembolism because they develop
smaller and fewer organized intravascular thrombi
comparing to wild-type animals. Mice treated with anti-
Gas6 antibodies display the same phenotype, and are
equally protected against fatal thromboembolism.12,13
Other reports indicate a possible role for Gas6 protein in
control of innate immunity and in inflammation processes.
Axl /, Mer / and Tyro 3 / mice display hyper-
activation of monocytes/macrophages with a higher
susceptibility to endotoxic shock and consequent mortality;
their monocytes react with an excessive secretion of tumor
necrosis factor (TNF)-a and interleukin (IL)-6 after lipo-
polysaccharides (LPS) challenge.14,15 Some authors have
also suggested the potential involvement of Gas6 in acute
inflammation in humans because plasma Gas6 concentra-
tions were found to be significantly increased in patients
affected by septic shock in intensive care units.16,17 Data
relating to the plasma concentration of Gas6 in humans
with PE are not available.a-related diagnoses.
Criteria
Absence of clinical or instr
(all patients discharged wi
re
Clinical signs of systemic o
pulmonary congestion; or
One of the following: (a) c
cultures positive or chest r
(not severe) according to I
Positive CT angiography of
for PE confirmed by signifi
anticoagulation with low mPE and pulmonary or systemic infections are common
causes of acute dyspnea. We tried to evaluate if plasma
Gas6 concentration varied among different causes of acute
dyspnea; this could aid differential diagnosis in patients
with acute dyspnea and suspected PE.
Methods
Patients
From March 2005 to August 2008 we enrolled 82 consecutive
patients with acute dyspnea due to suspected PE in the
present observational study. Inclusion criteria were: acute
dyspnea onset within the last 24 h and one of two findings:
(1) Geneva18 score 9 (high clinical probability for
PEdHCP); or (2) Geneva score <9 (low/intermediate clin-
ical probability for PEdLICP) together with plasma D-dimer
value 0.5 mg/mL. Patients were aged >18 years and gave
written informed consent. At the beginning of the enroll-
ment a review board was not required for observational
studies. Patients were excluded if plasma creatinine was
3 mg/dL, if they suffered from a primitive or secondary
pulmonary cancer, or if they were being treated with oral
warfarin.
All patients included were evaluated for PE diagnosis
according to in-use medical practice with either thorax
contrast-enhanced multidetector spiral computed tomog-
raphy (CT angiography) or with pulmonary perfusion scin-
tigraphy (111 MBq of 99mTc-MAA mean dose).
At enrollment, before any imaging exam, a 20-mL blood
sample was drawn from enrolled patients. Plasma and
serum samples were obtained within 1 h after centrifuga-
tion and stored at 80 C. Gas6 was measured at the end of
the enrollment.umental evidence of acute cardiac or pulmonary disease
thin 12 h from the emergency department of our hospital)
r pulmonary congestion þ chest radiograph supportive of
echocardiogram supportive of a reduced cardiac output28
linical signs of infection (fever, chills) þ blood or sputum
adiograph supportive of pneumonia; (b) diagnosis of sepsis
SDC criteria29
thorax or scintigraphy lung perfusion with high probability
cant improvement or resolution of PE after at least 7 days of
olecular weight heparin or oral warfarin
Gas6 in pulmonary embolism diagnosis 591Clinical data and the other instrumental examination
results were used to classify patients into one of four
groups: absence of acute cardiopulmonary illness (for
example anxiety) (N), acute heart failure (HF), pulmonary
or systemic infection including chronic obstructive pulmo-
nary disease (COPD) exacerbations (I), and pulmonary
embolism (PE). The definitions and diagnostic criteria used
for these groups are described in Table 1. Patients with
a combination of causes of dyspnea (e.g. COPD exacerba-
tion and acute heart failure) were not considered. Two
physicians defined all the diagnoses independently.
Discordant diagnoses were revaluated and assigned by
consensus.
A group of 29 volunteers age-matched to patients were
enrolled if they were healthy, except for arterial hyper-
tension under treatment. Healthy controls had 20 mL of
blood taken, and samples processed as described above.
Laboratory analysis
Blood gas data, without oxygen supplementation, and
plasma creatinine were assayed in automated laboratory
equipment (ADVIA 1650, Bayer Diagnostics Italia). D-dimer
was assayed with VIDAS D-dimer enzyme-linked fluorescent
assay on an automated immunoassay system (bioMe´rieux
Italia).
Gas6 protein was measured with a sandwich enzyme-
linked immunoassay (ELISA). Themethod has been validated
according to FoodandDrugAdministration (FDA) guidelines19
in a previous study (inter-assay and intra-assay %CVs were
within 15%, mean recovery on 15 patients of 96%, lower limit
of quantificationdLLOQd0.25 ng/mL).20 Briefly, a 96-well
plate (NUNC ImmunoPlates, UK) was coated overnight with
anti-Gas6 primary antibody (Goat polyclonal affinity purified
IgG, R&D Systems, Minneapolis, USA). Antigen was detected
by a secondary biotin-conjugated antibody (Biotinylated
anti-human Gas6 antibody, R&D Systems, USA) and a strep-
tavidineperoxidase conjugate (Sigma, USA) and TMB
(3,30,5,50-tetramethylbenzidine, Sigma, USA). The reaction
was blocked with 1.8 M sulfuric acid; absorbance was
detected at 450 nm with a reference wavelength set at
570 nm. Optical density was fitted versus nominal concen-
tration, applying a four-parameter logistic regression to the
calibration curve prepared in Gas6-depleted human plasma
with human recombinant Gas6 addition (R&D, USA).20
Statistical analysis
Data were analyzed with appropriate statistical software
(Statsoft). The ShapiroeWilk test was done to assessTable 2 Patient characteristics of dyspnea groups.
N8 HF12
Gas6 (ng/mL) 20.4 [17.6e21.6] 26.4 [21.6
D-dimer (mg/mL) 0.80 [0.64e1.22] 1.16 [0.87
PO2 (mmHg) 75.6 [75.0e77.9] 69.3 [65.0
PCO2 (mmHg) 33.1 [31.6e34.6] 33.7 [30.1
Creatinine (mg/dL) 0.9 [0.8e1.2] 1.3 [1.1e
Age (years) 66.5 [45.5e74] 74 [69.5enormality of each variable in any group. Median values,
together with interquartile range (IQR), were reported.
Median values of each group were compared with Kruskale
Wallis H-test (variance) and with KruskaleWallis test in case
of multiple comparisons or with ManneWhitney U-test for
comparisons between two groups. For Gas6 and D-dimer
accuracy, measurements were calculated at confidence
intervals (CIs) of 95%, together with positive likelihood
ratio.
Results
Out of the 82 patients enrolled, 60 were included; 8 were
N, 12 had HF, 11 had I, and 29 had PE. Of the 22 excluded, 9
patients were already being treated with anticoagulation
(p.o.), 6 patients lacked a CT angiography or evidence of PE
resolution with pulmonary scintigraphy, 3 patients had
plasma creatinine >3 mg/dL, and 4 patients suffered from
a primitive pulmonary cancer. All patients included dis-
played D-dimer values higher than 0.5 mg/mL. All variables
analyzed did not have a normal distribution in any diag-
nostic group (ShapiroeWilk, p > 0.05).
Gas6 median concentration was equivalent in the N and
healthy volunteers groups (20.4 ng/mL (17.6e21.6) and
19.1 (17.2e21.4) respectively) (ManneWhitney U-test,
pZ not significant (n.s.)). Gender did not influence Gas6
concentration within each group in healthy controls
(ManneWhitney U-test, pZ n.s.).
Table 2 details patients’ characteristics; there were no
significant differences in age and plasma creatinine
concentration among groups (KruskaleWallis variance,
p > 0.1). Table 2 and Figure 1 also report median plasma
Gas6 concentration of each group. In non-parametric post-
hoc comparisons, median plasma Gas6 concentration in HF
group or I group patients was higher than in those of PE or N
groups (KruskaleWallis test for multiple comparisons, N vs.
HF pZ 0.05, N vs. I p < 0.002, I vs. PE p < 0.0001, I vs. N
p < 0.002). Plasma Gas6 concentration was also higher in
the I group than the HF group though it was not significant,
and was nearly identical compared to PE and N groups
(ManneWhitney U-test, pZ 0.9).
We evaluated the usefulness of Gas6 as a diagnostic test
for PE. D-dimer 0.5 mg/mL determined a 52% [95% CI 39e65]
false positive rate. Gas6 testing on D-dimer positive
subjects displayed high true positive and low false positive
rates for several cut-offs tested with a greater performance
in patients with LICP for PE (Geneva score <9) (Table 3).
Moreover, as shown in receiver operator characteristics
curve analysis of Figure 2, area under the curve (AUC) of
Gas6 in PE diagnosis was 0.80 for all patients and 0.91 forI11 PE29
e33.3] 34.1 [30.0e38.7] 18.2 [16.3e23.3]
e1.39] 1.41 [0.95e1.86] 1.89 [1.22e9.21]
e76.9] 61.4 [58.3e65.0] 61.5 [54.7e68.0]
e36.0] 30.7 [26.6e37.3] 32.1 [30.0e33.9]
1.6] 1.4 [1.2e1.7] 1.1 [0.9e1.3]
79] 80 [70e84] 75 [66.5e80]
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20
25
30
35
40
45
Gas6
(ng/ml)
N
HF
I
PE
Figure 1 Plasma Gas6 concentration with median values
reported as horizontal lines for any group analyzed. See text
for statistical comparisons and explanations.
592 P.P. Sainaghi et al.subjects with LICP for PE. Finally, given a Gas6 plasma level
24 ng/mL, PE could be excluded in 16 out of 48 (33%)
patients with LICP for PE and D-dimer 0.5 mg/mL
(Table 4).
Discussion
Since gas6 is involved in PE or systemic inflammation in
animals,12e15 we evaluated plasma Gas6 protein concen-
tration in humans in relation to different causes of acute
dyspnea.
We measured a median concentration of 19.1 ng/mL in
healthy volunteers, which was nearly identical to that
observed in young healthy donors in a previous study.20 A
group from Sweden obtained very similar results applying
a different ELISA method.21 Researchers from France
obtained a Gas6 concentration of 52.0 ng/mL and 63.8 ng/
mL in healthy men and women, respectively.22 Although we
cannot exclude ethnic or geographical variations, we
suggest that differences in assay methods could explain this
discrepancy.
Our results demonstrated that a Gas6 protein test could
be useful for the differential diagnosis of acute dyspnea:Table 3 Accuracy of different Gas6 cut-offs in PE diagnosis.
All patients nZ 60 Sensitivity (%) 62 [42e
1  specificity (%) 26 [13e
Positive LR 2.4 [1.2
Negative LR 0.5 [0.3
Gas6 cut-off (ng/mL) <21
Patients with LICP nZ 48 Sensitivity (%) 80 [56e
1  specificity (%) 29 [14e
Positive LR 2.8 [1.5
Negative LR 0.2 [0.1Gas6 assay substantially increased D-dimer predictive value
in defining PE diagnosis. This effect was even more
apparent in patients with low to intermediate clinical
probability for PE. This fact is important since the patients
with loweintermediate probability for PE display a higher
proportion of false positivity on the D-dimer test. Therefore
these two tests used in combination could more accurately
identify PE, helping the clinician to avoid further expensive
instrumental work-up (pulmonary scintigraphy or CT
angiography).
Plasma Gas6 concentration was increased by about two
times the normal value in patients with acute dyspnea due
to pulmonary or systemic infection. This finding confirms
the hypothesis that Gas6 protein may be involved in acute
inflammation: a monocyteemacrophage hyperactivation
has been described in mice lacking Gas6 receptors14,15 and
plasma Gas6 concentration increases in patients with
severe sepsis, proportionally to disease severity.16,17 Thus
Gas6 seems to be involved in macrophage function, being
a possible biomarker of this activity.
We also demonstrated a 1.5-fold increase in plasma Gas6
concentration in subjects suffering from acute HF with
respect to baseline values. The elevation of inflammation
biomarkers and in particular of cytokines involved in innate
immunity, such as TNF-a, in HF is well documented.23e25
Gas6 elevation may be interpreted as an indicator of innate
immunity activation in this setting.
Gas6 protein was found to be expressed in mouse
platelets, secreted after platelet activation and bound to
Gas6 receptors on the platelet surface, suggesting an
autocrine stimulatory mechanism; moreover gas6 /
mice were protected from fatal thromboembolism similar
to wild-type mice treated with anti-Gas6 antibodies,
without alteration in bleeding.12,13 Platelet aggregates of
Gas6 / mice are loosely packed with few contact sites,
and are incompletely degranulated.26 All these data
suggest that Gas6 interaction with its receptors is important
in thrombus stabilization, possibly through an outside-in
signaling involving the integrin aIIbb3; however the inter-
action of Gas6 with its receptors is involved only in ampli-
fying the response of other platelet agonists but not
determining platelet activation by itself, as is true for other
molecules such as Eph kinases and ephrins or CD40 ligand.26
Additionally, Gas6 binds to its receptors through a domain
that needs a vitamin K dependent g-carboxylation to be
active, tightly linking this protein to hemostatic
processes.27 In contrast to the evidences exposed above,79] 86 [67e95] 100 [85e100] 100 [85e100]
45] 39 [22e58] 48 [31e67] 58 [39e75]
e4.7] 2.2 [1.4e3.5] 2.1 [1.4e3.0] 1.7 [1.3e2.3]
e0.8] 0.2 [0.1e0.6] 0 [0.0e0.0] 0 [0.0e0.0]
<24 <27 <30
93] 100 [80e100] 100 [80e100] 100 [80e100]
49] 43 [25e63] 50 [31e69] 61 [41e78]
e5.2] 2.3 [1.5e3.6] 2.0 [1.4e3.0] 1.6 [1.2e2.1]
e0.5] 0.0 [0.0e0.0] 0.0 [0.0e0.0] 0.0 [0.0e0.0]
1-specificity
se
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Figure 2 Receiver operator characteristics (ROC) curves of
Gas6 testing in all patients included (black circles) and in
subjects with low-intermediate probability for PE (open
triangles). The equations of fitted ROC curves are:
yZ 0.2Ln(x) þ 1, R2Z 0.99, AUCZ 0.80 (all patients) and
yZ 0.09Ln(x) þ 1, R2Z 0.93, AUCZ 0.91 (low-intermediate
probability for PE) respectively.
Gas6 in pulmonary embolism diagnosis 593we found that PE does not influence plasma Gas6 concen-
tration in humans. The simplest explanation for this
discrepancy is that Gas6 may be important for thrombus
formation but it is not overexpressed or released during
platelet aggregation or during the coagulation process,
perhaps acting as a membrane protein for platelets or
endothelial cells.12,13 It should also be considered that
other authors have raised concerns about Gas6 function in
human hemostasis: they failed to find Gas6 protein
expression in human platelets, suggesting that it may not
be as relevant in humans as it is in mice.21 Our data seem to
support the latter hypothesis; however, further research is
needed to clarify Gas6 function in human hemostasis.
In conclusion, plasma Gas6 concentration is increased in
patients with acute dyspnea due to HF and even more in
patients with systemic or pulmonary infection; Gas6
concentration in PE is unaffected. These data confirm the
hypothesis that Gas6 protein is involved in inflammation
and in particular in activation of innate immunity. Gas6
testing considerably improved the accuracy of the D-dimer
test in PE diagnosis, limiting false positives. However, theTable 4 Patient distribution after Gas6 test.
All patients Diagnosis Patients with LICP
nZ 60 nZ 48
Gas6 <27 n Gas6 27 Gas6 <24 n Gas6 24
29 29 0 PE 20 20 0
1 11 10 I 0 9 9
6 12 6 HF 5 11 6
8 8 0 N 7 8 1
44 (73%) 60 16 (27%) 32 (67%) 48 16 (33%)clinical utility of plasma Gas6 detection in the differential
diagnosis of acute dyspnea in PE evaluation must be
confirmed in a larger study.
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